Acta Med. 2006, 49: 161-165

https://doi.org/10.14712/18059694.2017.126

Contribution of Immunohistochemistry in Prognostic Assessment of Epithelial Ovarian Carcinoma – Review of the Literature I.

Markéta Tomšováa, Bohuslav Melicharb

aCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Fingerland Department of Pathology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Oncology and Radiotherapy, Hradec Králové, Czech Republic

Received June 1, 2006
Accepted July 1, 2006

References

1. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A, Sasano H. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 2000; 83:1488–94. <https://doi.org/10.1054/bjoc.2000.1463> <PubMed>
2. Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004; 10:5168–77. <https://doi.org/10.1158/1078-0432.CCR-03-0751>
3. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50:4087–91.
4. Berker B, Dunder I, Ensari A, Cengiz SD, Simsek E. Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2002; 23:505–10.
5. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 2004; 15:104–12. <https://doi.org/10.1093/annonc/mdh021>
6. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82:532–7. <https://doi.org/10.1006/gyno.2001.6328>
7. Dogan E, Saygili U, Tuna B, Gol M, Gurel D, Acar B, Koyuncuoglu M. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005; 97:46–52. <https://doi.org/10.1016/j.ygyno.2004.12.053>
8. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001; 194:68–75. <https://doi.org/10.1002/path.857>
9. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G, Biagini G. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56:169–74. <https://doi.org/10.1006/gyno.1995.1026>
10. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000; 77:278–82. <https://doi.org/10.1006/gyno.2000.5780>
11. Geisler HE, Geisler JP, Miller GA, Geisler MJ, Wiemann MC, Zhou Z, Crabtree W. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 2001; 92:781–6. <https://doi.org/10.1002/1097-0142(20010815)92:4<781::AID-CNCR1383>3.0.CO;2-P>
12. Goff BA, Muntz HG, Greer BE, Tamimi HK, Gown AM. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol 1998; 92:88–93. <https://doi.org/10.1016/S0029-7844(98)00121-5>
13. Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J, Ben- Baruch G. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol Oncol 2001; 82:99–104. <https://doi.org/10.1006/gyno.2001.6208>
14. Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J, Leake R. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990; 65:486–91. <https://doi.org/10.1002/1097-0142(19900201)65:3<486::AID-CNCR2820650319>3.0.CO;2-C>
15. Hempling RE, Piver MS, Eltabbakh GH, Recio FO. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 1998; 21:447–51. <https://doi.org/10.1097/00000421-199810000-00005>
16. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 1999; 59:3206–14.
17. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard- Pedersen B, Hogdall CK. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003; 98:66–73. <https://doi.org/10.1002/cncr.11476>
18. Hogdall EV, Kjaer SK, Blaakaer J, Christensen L, Glud E, Vuust J, Hogdall CK. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish „MALOVA“ ovarian cancer study. Gynecol Oncol 2006; 100:76–82. <https://doi.org/10.1016/j.ygyno.2005.07.131>
19. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47:159–66. <https://doi.org/10.1016/0090-8258(92)90100-W>
20. Huettner PC, Weinberg DS, Lage JM. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 1992; 141:699–706.
21. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Trope C. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005; 15:1014–22. <https://doi.org/10.1111/j.1525-1438.2005.00185.x>
22. Kim YT, Kim JW, Lee JW. c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. Cancer Lett 1998; 132:91–7. <https://doi.org/10.1016/S0304-3835(98)00162-1>
23. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47:317–22. <https://doi.org/10.1016/0090-8258(92)90133-4>
24. Kurman RJ. Blaustein’s Pathology od the Female Genital Tract. Fifth Edition. Springer-Verlag, New York, Berlin, Heidelberg, 2002:791–904.
25. Laframboise S, Chapman W, McLaughlin J, Andrulis IL. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J 2000; 6:302–8.
26. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K, Nagata I. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35:1214–9. <https://doi.org/10.1016/S0959-8049(99)00124-0>
27. Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, Klein M, Leodolter S, Mullauer-Ertl S, Rosen A, et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol 1995; 59:321–6. <https://doi.org/10.1006/gyno.1995.9969>
28. Münstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 2000; 89:1783–1791. <https://doi.org/10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D>
29. Murdoch WJ. Perturbation of sheep ovarian surface epithelial cells by ovulation: evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity. J Endocrinol 1998; 156:503–8. <https://doi.org/10.1677/joe.0.1560503>
30. Murdoch WJ, Van Kirk EA. Oestradiol inhibits spontaneous and cisplatin-induced apoptosis in epithelial ovarian cancer cells: relationship to DNA repair capacity. Apoptosis 1997; 2:478–84. <https://doi.org/10.1023/A:1026426212366>
31. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:1086–96. <https://doi.org/10.1111/j.1048-891X.2004.14606.x>
32. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138–50. <https://doi.org/10.1200/JCO.1991.9.7.1138>
33. Ozalp SS, Yalcin OT, Basaran GN, Artan S, Kabukcuoglu S, Minsin TH. Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer. Eur J Gynaecol Oncol 2000; 21:282–6.
34. Reitmaier M, Rudlowski C, Biesterfeld S, Rath W, Schroder W. Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma. Zentralbl Gynakol 2000; 122:361–7.
35. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El- Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7:2984–97.
36. Röhlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Loning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 1997; 123:496–501. <https://doi.org/10.1007/BF01192204> <PubMed>
37. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993; 168:162–9. <https://doi.org/10.1016/S0002-9378(12)90907-2>
38. Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks JH, Ward T, Buckley CH, Reynolds K, Slade RJ, Jayson GC. p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000; 36:2317–28. <https://doi.org/10.1016/S0959-8049(00)00301-4>
39. Sevelda P, Denison U, Schemper M, Spona J, Vavra N, Salzer H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol 1990; 97:706–12. <https://doi.org/10.1111/j.1471-0528.1990.tb16243.x>
40. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89:2006–17. <https://doi.org/10.1002/1097-0142(20001101)89:9<2006::AID-CNCR18>3.3.CO;2-Z>
41. Slotman BJ, Nauta JJ, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 1990; 66:740–4. <https://doi.org/10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H>
42. Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol 2004; 94:735–9. <https://doi.org/10.1016/j.ygyno.2004.05.055>
43. Tavasolli A, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: World Health Organization Classification of Tumours. IARC Press, 2003, Lyon, 117–145.
44. Tomsova M, Melichar B, Sedlakova I, Nova M. Prognostic markers in ovarian carcinoma – retrospective study. Cesk Patol 2005; 41:51–9.
45. van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG. Value of P-glycoprotein, glutathione S-transferase pi, cerbB- 2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13:70–8. <https://doi.org/10.1200/JCO.1995.13.1.70>
46. Werness BA, Freedman AN, Piver MS, Romero-Gutierrez M, Petrow E. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 1999; 75:413–8. <https://doi.org/10.1006/gyno.1999.5601>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive